Article: High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleHigh serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
AuthorsPoon, RTP1
Lau, C1
Pang, R1
Ng, KK1
Yuen, J1
Fan, ST1
KeywordsHepatocellular carcinoma
Radiofrequency ablation
Tumor biomarker
Vascular endothelial growth factor
Issue Date2007
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
CitationAnnals Of Surgical Oncology, 2007, v. 14 n. 6, p. 1835-1845 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-007-9366-z
AbstractBackground: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods: Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results: The median serum VEGF level in the HCC patients was 240 pg/mL (range 17-1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions: High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features. © 2007 Society of Surgical Oncology.
ISSN1068-9265
2011 Impact Factor: 4.166
2011 SCImago Journal Rankings: 0.358
DOIhttp://dx.doi.org/10.1245/s10434-007-9366-z
ISI Accession Number IDWOS:000247470300009
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorPoon, RTP
dc.contributor.authorLau, C
dc.contributor.authorPang, R
dc.contributor.authorNg, KK
dc.contributor.authorYuen, J
dc.contributor.authorFan, ST
dc.date.accessioned2010-09-06T06:36:18Z
dc.date.available2010-09-06T06:36:18Z
dc.date.issued2007
dc.description.abstractBackground: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods: Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results: The median serum VEGF level in the HCC patients was 240 pg/mL (range 17-1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions: High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features. © 2007 Society of Surgical Oncology.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationAnnals Of Surgical Oncology, 2007, v. 14 n. 6, p. 1835-1845 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-007-9366-z
dc.identifier.doihttp://dx.doi.org/10.1245/s10434-007-9366-z
dc.identifier.epage1845
dc.identifier.hkuros137545
dc.identifier.isiWOS:000247470300009
dc.identifier.issn1068-9265
2011 Impact Factor: 4.166
2011 SCImago Journal Rankings: 0.358
dc.identifier.issue6
dc.identifier.openurl
dc.identifier.pmid17406950
dc.identifier.scopuseid_2-s2.0-34249900712
dc.identifier.spage1835
dc.identifier.urihttp://hdl.handle.net/10722/71902
dc.identifier.volume14
dc.languageeng
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
dc.publisher.placeUnited States
dc.relation.ispartofAnnals of Surgical Oncology
dc.relation.referencesReferences in Scopus
dc.rightsThe original publication is available at www.springerlink.com
dc.subject.meshCarcinoma, Hepatocellular - blood - surgery
dc.subject.meshCatheter Ablation
dc.subject.meshLiver Neoplasms - blood - surgery
dc.subject.meshTumor Markers, Biological - blood
dc.subject.meshVascular Endothelial Growth Factor A - blood
dc.subjectHepatocellular carcinoma
dc.subjectRadiofrequency ablation
dc.subjectTumor biomarker
dc.subjectVascular endothelial growth factor
dc.titleHigh serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong